Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.71 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25566685 | 0.90 | ADORA3 (0.82) | ADORA3ADORA1HSP90B1TMIGD3 | |
| SCHEMBL19799152 | 0.89 | ADORA3 (0.80) | ADORA3ADORA1TMIGD3 | |
| SCHEMBL25612586 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1HSP90B1TMIGD3 | |
| SCHEMBL25566677 | 0.88 | ADORA3 (1.00) | ADORA3ADORA1TMIGD3 | |
| SCHEMBL25566630 | 0.86 | ADORA3 (0.75) | ADORA3ADORA1TMIGD3 | |
| SCHEMBL25566749 | 0.84 | ADORA3 (0.82) | ADORA3ADORA1TMIGD3 | |
| SCHEMBL19459913 | 0.84 | HSP90B1 (0.80) | ADORA3ADORA1HSP90B1TMIGD3 | |
| SCHEMBL19799159 | 0.84 | HSP90B1 (0.80) | ADORA3ADORA1HSP90B1TMIGD3 | |
| SCHEMBL30255447 | 0.84 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL16774178 | 0.84 | ADORA3 (1.00) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825126-B2 | Purine derivatives as A3 and A1 adenosine receptor agonists | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232626-A1 | Purine Derivatives as A3 and A1 Adenosine Receptor Agonists | ADORA1, ADORA3, ADORA2A | ADORA3 2/4885ADORA1 1/4885HSP90B1 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.